Purpose. Clostridium difficile infection (CDI) is an increasing cause of nosocomial diarrhoea worldwide, which has been partly attributed to the emergence of hypervirulent strains including C. difficile BI/NAP1/ribotype 027 and BK/NAP7/ribotype 078. Cadazolid is a new antibiotic currently in late-stage clinical studies for the treatment of CDI. The present study evaluated the in vitro bactericidal effect of cadazolid and comparator antibiotics against four C. difficile strains. The data demonstrate the potent and bactericidal activity of cadazolid against different ribotypes of C. difficile.
INTRODUCTION
Clostridium difficile is a Gram-positive, obligately anaerobic, spore-forming bacterium that is one of the leading causes of nosocomial diarrhoea worldwide. The spores of C. difficile are extremely tolerant of many commonly used disinfectants and can persist in the environment for extended periods of time, likely aiding the dissemination of C. difficile in the hospital setting [1] . Colonization of the colon by toxigenic C. difficile is facilitated by the disruption of the normal host flora following therapy with certain antibiotics, such as fluoroquinolones, cephalosporins and clindamycin. C. difficile infection (CDI) can be a severe and life-threatening disease mainly affecting elderly hospitalized patients, though in recent years this disease has also affected relatively healthy adults, including some with no previous exposure to the hospital environment [2] . The increase in frequency and severity of CDI over the past two decades has been attributed, at least partly, to the emergence of hypervirulent strains including C. difficile BI/NAP1/ribotype 027 and BK/ NAP7/ribotype 078 [3] . Vancomycin and metronidazole have been used as first-line therapy for mild to severe CDI for the past 30 years with only one new drug, fidaxomicin, being approved during this time. Although cure rates for the initial episode of CDI are high, approximately 15-40 % of patients experience recurrence of the disease, depending on the choice of antibiotic [2, 4, 5] . In clinical studies fidaxomicin showed reduced recurrence rates compared to vancomycin, but recurrence rates for fidaxomicin were still high for infections involving the hypervirulent strain NAP1/ BI/027 (24 % recurrence rate) [4, 6] . Therefore, there is a clear need for new therapeutic options that allow effective treatment of CDI, particularly caused by hypervirulent strains, with low recurrence rates.
Cadazolid is a novel antibiotic in development for the treatment of CDI. Its chemical structure represents a new antibacterial class, referred to as the quinoxolidinones, combining elements of an oxazolidinone moiety with a fluoroquinolone moiety resulting in unique properties [7, 8] . Previous studies have shown that cadazolid is an inhibitor of C. difficile protein synthesis leading to suppression of toxin and spore formation [8, 9] . In preclinical studies cadazolid showed potent in vitro activity against C. difficile clinical isolates. Similarly, strong effects on C. difficile were observed in a human gut model of CDI, together with very limited impact on bacteria of the normal gut microflora [10, 11] . In addition, cadazolid demonstrated a low propensity for resistance development [7, 8] . In a Phase 2 trial for treatment of CDI, cadazolid demonstrated clinical cure rates similar to vancomycin with lower recurrence rates [12] . Two Phase 3 trials in CDI have been completed recently (NCT01983683, NCT01987895).
Few data on the bactericidal effect of cadazolid against C. difficile are available. Therefore, the aim of this study was to investigate the in vitro bactericidal activity of cadazolid by time-kill kinetics studies, in comparison to vancomycin and fidaxomicin, against a panel of four C. difficile strains from ribotypes 027, 078, 087 and 001.
METHODS
Bacterial strains and test articles C. difficile strains (Table 1) were recovered from long-term storage at À80
C by culturing on a pre-reduced Columbia blood agar base (Oxoid, Basingstoke, UK) supplemented with 5 % (v/v) defibrinated horse blood (Oxoid) for 48 h at 37 C in a Whitley A85 anaerobic workstation supplied with a gas mixture of 80 : 10 : 10 N 2 : CO 2 :H 2 . Thereafter, bacterial strains were maintained on pre-reduced C. 
Antibiotic susceptibility testing
The MIC of test antibiotics was determined in brain-heart infusion (BHI) broth (Oxoid) containing 5 g l À1 yeast extract (Oxoid) and 0.025 % (w/v) L-cysteine (Apollo, Staffordshire, UK), the resulting formulation being designated as BHIS broth. Assays were performed following the broth microdilution method described in the Clinical and Laboratory Standards Institute (CLSI) guidelines M11-A7 [13] and M100-S28 [14] , but using BHIS medium, which has previously been validated by Corbett et al. [15] for C. difficile time-kill kinetic studies. Controls (antibiotic and QC organism) were included in this work to confirm the suitability of this medium for antibiotic susceptibility testing. Briefly, test articles were serially diluted in 96-well micro-titre plates containing BHIS broth, which were then pre-reduced overnight. Assay plates were subsequently inoculated with 1Â10 6 c.f.u. ml À1 of C. difficile and further incubated for 48 h under anaerobic conditions at 37 C. Endpoints were determined by spectrophotometer (BioTek Synergy 2, Swindon, UK) at 600 nm, whereby the MIC was defined as the lowest concentration of antibiotics required to inhibit bacterial growth compared to growth and broth-only controls (!95 % inhibition). MIC results were determined from independent triplicate assays carried out on separate days.
Time-kill kinetic studies
Starter cultures of C. difficile were prepared by inoculating 20 ml BHIS broth with a single colony of the required strain. T -Type strain [25] . Isolate used in [9] ATCC BAA 1875 078 Isolated in Georgia, USA [20, 21, 23, 26] ATCC 700057 038 CLSI-recommended quality control strain for susceptibility testing [13] T, Type strain.
withdrawn at each time point, centrifuged (1 min at 16 000 g) and washed twice in sterile pre-reduced PBS (Oxoid) to reduce residual drug carryover, before 10-fold serial dilutions were performed prior to plating on BHIS agar [16] . Agar plates were incubated for up to 24 h, following which the number of viable C. difficile (c.f.u. ml
À1
) was determined. In addition, samples were taken at T0 and T48 in order to determine the proportion of the viable population that existed as spores for each experimental condition following the method described by Burns et al. [17] . Briefly, duplicate samples were removed, one of which was incubated at 60 C for 25 min to kill vegetative bacteria while the other was immediately used to determine the total viable count; both were then plated on BHIS supplemented with 0.1 % (w/v) sodium taurocholate hydrate (Sigma, Watford, UK) to maximize germination. Experiments were performed in triplicate on separate days. The limit of detection (LoD) for killing kinetic assays was 50 c.f.u. ml À1 . Bactericidal activity refers to a reduction of !3 log 10 in viability relative to the starting inoculum after 24 h exposure to antibiotics.
Statistical analysis
Log 10 c.f.u. ml À1 reductions achieved by antibiotics against the four C. difficile strains in the kill kinetics studies and the significance of remaining spore populations following 48 h antibiotic exposure were compared using the KruskalWallis test corrected for multiple comparisons (ConoverInman). Statistical analysis was performed using StatsDirect software (StatsDirect Ltd), and P values of 0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Antibiotic susceptibility testing The modal MICs of cadazolid, vancomycin and fidaxomicin against each isolate are summarized in Table 2 . Although not performed strictly to CLSI guidelines, due to the use of liquid growth medium, vancomycin and cadazolid susceptibilities for the C. difficile ATCC 700057 reference control were within the CLSI-suggested agar dilution MIC ranges of 0.5-4 µg ml À1 and 0.12-0.5 µg ml
À1
, respectively, while the fidaxomicin MIC for this strain was 2-fold below the CLSI-suggested agar dilution MIC range of 0.06-0.25 µg ml À1 [14] . Cadazolid was 8-fold more potent than vancomycin against the C. difficile strains, generating low MICs of 0.125-0.25 µg ml
, and was comparable in activity to fidaxomicin (MIC range 0.008-0.25 µg ml À1 ), both of which were within published ranges [9, 18] .
Killing kinetics
The comparative killing kinetics of cadazolid, vancomycin and fidaxomicin against C. difficile strains during 48 h of exposure are described below, and complete kill curves at 0.5-16Â MIC for each antibiotic and strain are shown in the supplementary material (Figs S1-S4, available in the online version of this article). A direct comparison of the three agents tested at 0.5-2Â MIC is shown in Figs 1-4 . The starting inoculum for C. difficile isolates varied between 2Â10 5 and 1Â10 6 c.f.u. ml À1 in the time kill assays (Figs 1-4 ).
Cadazolid at !2Â MIC achieved bactericidal activity, defined as !3 log 10 c.f.u. ml À1 reduction in viability relative to the starting inoculum after 24 h antibiotic exposure, against three out of the four strains tested (Figs 1, 2 and 4) , which was significantly superior to killing by vancomycin (P 0.046). For ATCC 9689 T a reduction of approximately 2 log 10 c.f.u. ml
À1
was observed after 24 h; however, !3 log 10 c.f.u. ml À1 killing was achieved after 48 h in this strain (Fig. 3) . Notably, bactericidal activity was achieved against the hypervirulent ribotype 027 (Fig. 2) and 078 (Fig. 4) strains. At concentrations of 0.5Â MIC, cadazolid showed reduced growth rates against all strains, while at 1Â MIC it was inhibitory but not bactericidal (Figs 1-4) . Bactericidal effects were obtained at concentrations of !2Â MIC and the rate of killing did not substantially increase at higher cadazolid concentrations of 4-to 16-fold MIC (Fig. S4a) . Cadazolid killing rates were characterized by a relatively rapid drop in viable counts during the first 4-8 h followed by slower killing. Against ATCC 9689
T cadazolid quickly reduced the viability over the first 2 h (>1 log 10 c.f.u. ml
), but killing activity slowed considerably at later time points, reaching~2 log 10 c.f.u. ml À1 reduction by 24 h and !3 log 10 c.f.u. ml À1 reduction only after 48 h at 2-and 4-fold MIC (Figs 3, S3a) .
In comparison, vancomycin at !2Â MIC achieved bactericidal activity in 24 h against ATCC 9689 T , which was significantly better than killing by cadazolid (P=0.005) and fidaxomicin (P=0.001) against this strain (Figs 3, S3b) . After 48 h a reduction of 3-log 10 c.f.u. ml À1 was achieved in three strains, excepting BAA-1875 (ribotype 078), where vancomycin showed no bactericidal effect at all test concentrations (Fig. S4b) . Initial vancomycin-mediated killing was less rapid than for cadazolid. At 0.5Â MIC of vancomycin, initial reduction of viable counts was followed by re-growth after 24 h in all strains. In two strains (NTCC 13366 and ATCC 9689 T ) this was also observed for 1Â MIC vancomycin concentrations (Figs 2 and 3 ).
Fidaxomicin displayed a concentration-independent bactericidal effect in the range of 1-to 16-fold MIC, with bactericidal activity achieved after 24 h in two strains (ATCC BAA-1875 and NCTC 13366) and after 48 h in all strains (Fig. S1c-S4c ). In addition, fidaxomicin at !2Â MIC was significantly better at killing cells of ATCC BAA-1875 (post-24 h exposure; P=0.002) and NCTC 13366 (post-48 h exposure; P=0.008) compared to vancomycin (Figs 2 and 4) . At 0.5Â MIC, fidaxomicin showed a bactericidal effect with re-growth after 24 h in two out of four strains (NCTC 13366 and ATCC 9689 T ). Killing mediated by fidaxomicin appeared generally similar to that by cadazolid (P>0.05), with some inter-strain variations (Figs S1a, c and S4a, c).
Initial killing rates by fidaxomicin were slower than for cadazolid in three strains (NCTC 13366, ATCC BAA-1875 and ATCC 43255), while the former had a more prominent effect at 0.5Â MIC. Overall, these data are comparable to published time-kill studies with fidaxomicin and its metabolite [16] .
The effect of 48 h antibiotic exposure on C. difficile spore formation is shown in Table S1 . The mean spore populations present at the start (T0) and at the end (T48) of each killing kinetic experiment were determined for all C. difficile strain-antibiotic combinations. The number of spores present at the start of each time kill assay was relatively stable between replicate runs, with a small fraction of cells ( 0.6 %) existing as spores compared to the total viable population (data not shown). In the vehicle-only cultures of C. difficile ATCC 43255, NCTC 13366 and ATCC BAA-1875, spore populations at 48 h had increased by 4.2 (P>0.05), 3.8 (P=0.0016) and 3.1 (P=0.0003) log 10 c.f.u. ml À1 for the DMSO control and 4.4 (P>0.05), 4.1 (P=0.0003) and 3.3 (P=0.0003) log 10 c.f.u. ml À1 for the water control, respectively. Of note, for each of these strains the proportion of the population that existed as spores was below 11 % (3.5Â10 6 c.f.u. ml À1 ) of the total viable count following 48 h of growth (data not shown). There was also some inter-strain variability in the size of the spore populations of cultures post-48 h treatment with supra-MIC concentrations. Spore formation was significantly inhibited by 48 h exposure of cadazolid, vancomycin and fidaxomicin compared to the vehicle control in three out of four C. difficile strains (Table S1 ) -specifically, cultures of ATCC 43255 (!1Â CDZ, P=0.0327, !1Â VAN, P=0.028; !0.5Â FDX, P=0.0327), ATCC BAA-1875 (!4Â CDZ, P 0.0153; 2 and >4Â VAN, P 0.0473; !0.5Â FDX, P 0.0414) and NCTC 13366 (!0.5Â CDZ, P 0.0183; 1 and 8ÂVAN, P 0.0498; !1Â FDX, P 0.0091). For all strains tested, spore counts following 48 h exposure to !0.5Â MIC of all antibiotics were generally similar to the T0 values and near the limit of detection (P>0.05), except 0.5Â VAN for NCTC 13366 (P=0.007) and 0.5 to 1 and 4Â VAN for ATCC BAA-1875 (P 0.041) (Table S1 ). A limited increase of~0.5 log 10 c.f.u. ml À1 was also observed for BAA-1875 for all antibiotics tested (Table S1 ). Cadazolid and fidaxomicin have previously been reported to markedly inhibit the formation of spores at sub-MICs for up to 5 days [9] and 9 days [19] , respectively, while vancomycin had no inhibitory effect. Different definitions of sub-MIC (agar MIC, microdilution broth MIC and macrodilution MIC) may account for some variations observed within different studies.
In summary, the results of this investigation demonstrated the excellent in vitro activity of cadazolid against four isolates of C. difficile, generating low MICs (0.125-0.25 µg ml
) consistent with recently published literature [6, [8] [9] [10] . Based on data from the time-kill kinetic studies against this limited set of C. difficile strains, it appears that killing by cadazolid following 24 and 48 h exposure was superior to that of vancomycin and comparable to that of fidaxomicin. In addition, cadazolid-mediated killing was faster than that by vancomycin and fidaxomicin over an 8 h period for three of the four C. difficile isolates, including the fluoroquinolone-resistant hypervirulent ribotype 027 and 078 strains. The potent bactericidal activity of cadazolid is in agreement with results from the in vitro human gut model where cadazolid rapidly reduced the number of vegetative cells (4-5 log 10 c.f.u. ml À1 reduction) during the cadazolid instillation period at a dose equivalent to 250 mg b.i.d. for 7 days in humans, with no evidence of subsequent spore germination or proliferation [10] . In the present study, spore counts at 48 h post treatment with all antibiotics at >1Â MIC were generally close to the limit of detection and similar to those observed in pre-treatment cultures. None of the three antibiotics tested could eliminate spores present at the start of the experiment, and this pre-existing spore population present during the entire experiment represents a major part of the viable counts recovered post-48 h exposure.
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